Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celltech Group, Cistron, Connetics, Lonza Group Ltd. deal

CCH will acquire CIST for $18 million in CCH ADS's, consisting of $8.75 million for CIST's anti-interleukin (IL-1) antibodies to treat inflammatory disorders

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE